BFUHS Invites Applications For Master in Hospital and Health Administration Admissions 2024, check details

Punjab- The Baba Farid University of Health Sciences (BFUHS) has invited online applications for admission to the M.H.H.A. (Master in Hospital and Health Administration) Course for 2024. 

Interested candidates are advised to take note of the admission details for the MHHA course as mentioned below:

Walk-in-Counseling for admission to Master in Hospital and Health Administration (MHHA) Session, 2024 at the Department of Master in Hospital and Health Administration, University Centre of Excellence in Research (UCER), BFUHS, Faridkot will be held on 23/10/2024 (For in-service candidates also), along with requisite fee of Rs.5000/+18% GST (Rs.5900/-) and for SC candidates Rs.2500+18% GST (Rs.2950/-) Through University Payment Gateway.

Display of Final Merit List- 23/1012024 (11 am).

Time of Counselling/Venue- Department of Master in Hospital and Health Administration, BFUHS, Faridkot.

The last date for receipt of registration return/Fee for the provisional admitted candidates to the University is 31-11-2024.

Eligibility Criteria

A graduate degree in any health-related field such as MBBS, BDS, BPT, BOT, B.Sc.(N), BMLT, BAMS or in any other allied health sciences or any other admission criteria and qualifications notified by the Government of Punjab/Baba Farid University of Health Sciences, Faridkot, from time to time.

Duration of Course

02 years

Course Fee to be paid by the students (per annum)

Rs. 40,000/- The Selected candidates will pay the tuition fee (40,000/-) in the shape of Demand Draft in favor of Registrar, BFUHS payable at Faridkot or through online University gateway. 

No. of seats

30 seats are available for candidates.

To view the official Notice, Click here :  https://medicaldialogues.in/pdf_upload/prospectus-256364.pdf

Baba Farid University of Health Sciences, Faridkot is one among 13 Public Sector Universities of Health Sciences in the Country, which is making a niche in the Medical Education over last few years. It has 160 affiliated colleges of various health sciences education and about 35000 students are on roll with the University. In addition to the various courses pertaining to the health sciences, the University has unique distinction of running skill development courses in as many as 60 streams which is helpful to develop human resources which is a great need of the society.

These skill development Courses are in line with the thoughts of Hon’ble Prime Minister. The University is committed for transparency, accessibility and problem solving approach for the students and maintaining standards as per statutory bodies like NMC, PMC, PDC, DCI & INC. The University and its affiliated colleges are putting best efforts to enhance the facilities, so that ambience of better learning is created

Powered by WPeMatico

Quack running illegal clinic for 15 years in Odisha arrested

Balangir: In a decisive move aimed at safeguarding the public health infrastructure, a fake doctor was arrested following a raid in the Saintala area of Odisha’s Balangir district.

According to the Odisha Bytes, the sources revealed that the man without any medical qualification was running a clinic at Tikrapada under the jurisdiction of Saintala police station for the last 15 years in an illegal manner.    

The accused, a resident of West Bengal, had been running his clinic for over 15 years at Tikrapada without any formal medical qualifications. This incident raised concerns among the residents about the quality of care provided at the clinic.   

Following the raid conducted by the police and drug inspector, the accused was arrested. The raid was conducted in response to community concerns and this incident raises serious concerns about the public health safety in the region.   

During the raid, several medicines, injections, and other articles were seized from the illegal clinic. The presence of these unauthorized medicines raises several questions related to the patient safety of the region. Authorities are conducting a further investigation to uncover more details about the case.   

Also Read: Quack arrested for operating clinic in Thane

A similar incident was earlier reported by Medical Dialogues where a suspected fake doctor was detained by police at Fakir Mohan Medical College and Hospital in Balasore. The impersonation was discovered when medical personnel spotted a person prescribing medication to patients, which sparked obvious suspicion. When questioned about his credentials, the suspected impostor argued with the hospital’s security guard. The police detained the person from the hospital for additional interrogation. An investigation is underway to ascertain his identity and medical qualifications.    

Powered by WPeMatico

Merck Phase 3 trial of head and neck cancer treatment meets primary endpoint

Rahway: Merck, known as MSD outside of the United States and Canada,  has announced that the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative treatment for patients newly diagnosed with stage III or IVA, resected, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) met its primary endpoint of event-free survival (EFS).

The study evaluated KEYTRUDA as neoadjuvant therapy, then continued after surgery in combination with standard-of-care radiotherapy (with or without cisplatin) as adjuvant therapy, followed by KEYTRUDA as maintenance therapy, compared to adjuvant radiotherapy (with or without cisplatin) alone. At a pre-specified first interim analysis conducted by an independent Data Monitoring Committee, there was a statistically significant and clinically meaningful improvement in EFS for patients receiving the KEYTRUDA perioperative treatment regimen. The study also showed a statistically significant improvement in major pathological response (mPR), a key secondary endpoint, for patients in the KEYTRUDA arm compared with adjuvant radiotherapy alone. The safety profile of KEYTRUDA was consistent with that observed in previously reported studies; no new safety signals were identified.

“These results are substantial, as KEYNOTE-689 marks the first positive trial in two decades for patients with resected, locally advanced head and neck squamous cell carcinoma,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “These statistically significant and clinically meaningful findings have the potential to be practice-changing and continue to highlight the promising role of KEYTRUDA for certain patients with earlier stages of disease.”

A trend toward improvement in overall survival (OS), another key secondary endpoint, was observed for KEYTRUDA as neoadjuvant treatment and KEYTRUDA in combination with standard-of-care radiotherapy (with or without cisplatin) as treatment after surgery and maintenance therapy with KEYTRUDA. The OS results did not reach statistical significance in patients whose tumors were PD-L1 Combined Positive Score (CPS) ≥10 at the time of this first interim analysis. Due to the statistical testing hierarchy, formal testing was not performed in the CPS ≥1 and intention-to-treat (ITT) populations. OS will be evaluated at the next interim analysis.

Results will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.

KEYTRUDA is currently approved as monotherapy and in combination regimens for appropriate patients with metastatic or unresectable, recurrent HNSCC in the U.S., Europe, China, Japan and other countries around the world. 

Powered by WPeMatico

Three Scientists from Dr DY Patil Medical College earn spot in 2024 Stanford University’s Top 2% Global Researchers Ranking

Pune: Dr DY Patil Medical College, Hospital and Research Centre in Pimpri, Pune, proudly announces that three of its esteemed scientists—Dr. Amitav Banerjee, Professor of Community Medicine; Dr. Sarika Chaturvedi, Senior Scientist; and Dr. Sachin Atre, Research Consultant and Adjunct Faculty—have been recognized among the Top 2% Scientists in the World according to Stanford University’s prestigious 2024 global rankings.

This remarkable recognition highlights the institution’s commitment to world-class research and its contributions to global health.

According to an ANI report, Dr Amitav Banerjee has a distinguished research career spanning over four decades. His substantial body of work encompasses critical investigations into epidemics, including typhoid, hepatitis, respiratory infections and pneumonia.

Many of these pivotal studies were conducted during his tenure with the Indian Armed Forces. Dr. Banerjee’s research excellence in epidemiology, especially in the fields of tribal malaria and viral hepatitis, has earned him prestigious awards and recognition. His groundbreaking work on research methodology, population studies and sampling methodologies has garnered maximum citations.

Also Read:13 Indian Endocrinologists Shine in Top 2% Scientists in Stanford’s Global 2024 List

Notably, from 2000 to 2004, Dr. Banerjee led the Mobile Epidemic Investigation Team at the Indian Armed Forces. After voluntarily transitioning from the armed forces in 2005, he assumed the role of a professor at Dr. D. Y. Patil Medical College. Presently, he serves as the editor of the International Medical Journal of Dr. D. Y. Patil Vidyapeeth, Pune. He is working as Professor Emeritus at Dr. D. Y. Patil Medical College Pune & Editor in Chief of Medical Journal Dr. D. Y. Patil Vidyapeeth & Academic Editor of PLOS ONE.

Reflecting on this remarkable achievement, Dr. Amitav Banerjee said, “Successful research demands patience, dedication and perseverance. The true measure of research excellence lies in the recognition and citation of one’s work by fellow scholars. I consider myself fortunate to have served as an epidemiologist, which provided me with exceptional opportunities to investigate and combat outbreaks.”

Among the notable figures recognized in the Stanford list is the accomplished young scientist, Dr. Sarika Chaturvedi, who holds a Ph.D. from the prestigious Karolinska Institute in Sweden. Dr. Sarika’s research endeavours are primarily concentrated on public health and traditional medicine. She is mentored by Professor Bhushan Patwardhan, also a senior scientist featured on the Standford list.

The majority of her highly cited work stems from her diligent contributions to the public healthcare system, focusing on the assessment of disease burdens and estimates of disease risk factors. Her work delves into identifying populations at risk of diseases and their geographical distribution, historical alterations and future predictions. Dr. Sarika is currently engaged in two significant research projects. One pertains to the effect of ‘Government of India’s Common Yoga Protocol on brain functions in adults,’ and the other explores the potential health benefits of nasal oil instillation. Additionally, Dr. Sarika is currently serving as a fellow on the Lancet Citizens Commission to Reimagine India’s Health System.

Dr. Sarika, said, “Meaningful research that addresses societal challenges and promotes well-being requires a ‘gift of diverse perspectives.’ The dominance of Euro-Western knowledge systems, with their limited scope and disconnection from nature, has contributed to global crises that threaten planetary health. It is encouraging to see that India is increasingly supporting transdisciplinary research that embraces its rich indigenous knowledge systems. This offers great hope for groundbreaking research to emerge from India”, news agency ANI reported.

Dr. Sachin Atre, a medical anthropologist with over two decades of research experience in public health, has also earned a place in the esteemed Stanford list. Dr. Atre received his Ph.D. from the University of Pune and was honored with the prestigious Fulbright-Nehru Postdoc Fellowship at Harvard Medical School in the USA.

His significant contributions span research on tuberculosis and drug-resistant tuberculosis, as well as nutrition, diabetes, leprosy and access to medicines. He serves as an invited reviewer for The Lancet and Lancet group of journals and holds the role of an academic editor for PLOS Global Public Health. He has worked for World Health Organization (WHO), as a technical consultant for Global TB Program. Dr. Atre has an impressive portfolio with 76 publications, accumulating over 35,000 citations in SCOPUS.

Upon receiving recognition in the Stanford list, Dr. Sachin Atre expressed, “Public health research requires a deep commitment to both scientific integrity and the well-being of the community. It is essential that our work remains honest and transparent, with the ultimate goal of improving the health and welfare of those we serve. This recognition is a testament to the importance of keeping the community’s welfare at the center of all research efforts.”

Dr Yashraj Patil, Trustee and Treasure of Dr. D. Y. Patil Vidyapeeth (Deemed to be University), Pimpri, Pune remarked, “This incredible recognition is a significant milestone not just for the individual scientists but for the entire Dr. D. Y. Patil Medical College community. It reflects the research excellence, perseverance and dedication that our faculty bring to the forefront every day.

Being featured in Stanford’s top 2% list of scientists further validates the world-class research ecosystem we have built over the years. This achievement puts us on the global map and strengthens our commitment to nurturing an environment of academic and scientific excellence. We will continue to support and inspire our faculty to push the boundaries of innovation and contribute to solving the pressing challenges of global health. We are immensely proud of our scientists for bringing such honor to the institution.”

Dr. J. S. Bhawalkar, Dean of Dr. D. Y. Patil Medical College, Hospital & Research Centre, expressed his pride in the institution’s accomplishment, stating, “This achievement is a testament to the robust research culture we have fostered at Dr. D. Y. Patil Medical College, Hospital & Research Centre. Our institution has always prioritized innovation, academic excellence and the pursuit of knowledge that addresses global health challenges. This recognition highlights our commitment to creating an environment where cutting-edge research thrives and it reaffirms our position as a leader in medical education and research. We are immensely proud of our scientists and the role they play in shaping the future of healthcare.”

Also Read:12 Indian Cardiologists, Scientists Get Recognised in Standford University 2024 list of World’s Top 2% Scientists

Powered by WPeMatico

Pay back overcharged amount! Regulatory panel orders Apollo Gleneagles Hospital

Kolkata: Holding that the hospital overcharged the patient for a hernia operation,
the West Bengal Clinical Establishment Regulatory Commission (WBCERC) has
issued a directive to the Apollo Gleneagles Hospital.

In its order, the regulatory panel directed the hospital to set up a fixed deposit of Rs. 13,488 in
the name of a patient which can later used by the concerned patient for future treatments.

The panel found that the hospital had overcharged the said amount for a
hernia operation and deemed the charges to be “excessive”
and ‘beyond what was necessary.’

The case relates to an elderly patient who was
admitted to Apollo Gleneagles Hospital for a hernia surgery. While the hospital initially quoted a
package cost of Rs. 1.80 lakh, the insurance company only approved Rs. 50,000. He
was informed by an agent that the balance would be covered upon application approval to
the insurance company. However, the patient was required to pay Rs. 1.08 lakh
upfront, with the hospital eventually receiving Rs. 71,000.

The WBCERC discovered
that the hospital had charged an additional Rs. 13,448 for a mesh used during
the procedure, which should have been covered under the patient’s policy. As a
result, the commission directed the hospital to create a fixed deposit with the
same amount in the patient’s name to be used for future treatments.

In a separate case heard by the panel that day,
WBCERC instructed Fortis Hospital to refund Rs. 10,460 to the family of a
patient who passed away following complications from gallbladder surgery. The
refund pertains to non-medical expenses charged to the family and was ordered
on humanitarian grounds.

Powered by WPeMatico

New medical college in Gujarat’s Kadi gets NMC approval for 100 MBBS seats

Ahmedabad: In a boost to
medical education in Gujarat, the National Medical Commission (NMC) granted
permission to set up a new government medical institute, Bhagyoday Medical
College in the state with 100 MBBS seats.

The fee structure for Kadi Medical College, newly approved by the NMC, is yet to be finalized by the Fee Regulatory Committee (FRC). The college will apply separately for fee determination.

The state government submitted three applications for new medical
colleges for the academic year 2024-2025.

The applications included proposals
for new medical colleges in Rajkot, Junagarh, and Kadi. The new medical college
at Rajkot is supposed to have 150 MBBS seats while the medical college at Junagarh
is to start with 100 seats.

However, the proposal for both colleges has failed
to secure NMC approval, reports the Times of India.

Also Read:Brownfield Medical College Policy amended! 7 New Medical Colleges to Come Up in Gujarat

Previously Medical
Dialogues reported that seven new medical colleges are going up be set up in
the State as the Government amended its brownfield medical college policy. Seven
new medical colleges will be started in Botad, Devbhumi Dwarka, Gir-Somnath,
Kheda-Nadiad, Chhota Udepur, Mahisagar-Lunawada, and Dang-Ahwa.

The decision in this regard was taken at a cabinet meeting held at Gandhinagar under the chairmanship of Chief Minister Bhupendrabhai Patel.

The Brownfield Medical College Policy was introduced by the State Government in 2016 to start new medical colleges at the district-level government hospitals. At present, Gujarat has seven functional brownfield medical colleges including Palanpur (Banaskantha), Amreli, Dahod, Bharuch, and Tapi-Vyara.

Powered by WPeMatico

Hospital Slapped Rs 25 Lakh Compensation for Faulty Discharge Summary, Doctors Exonerated

New Delhi: The National Consumer Disputes Redressal Commission (NCDRC) recently directed Noida-based Kailash Hospital and Heart Institute to pay Rs 25 lakh compensation to a man, whose mother attained a vegetative state after undergoing treatment at the hospital.

Although the Commission exonerated the doctors holding that there was no medical negligence on their part, it noted that the discharge summary issued by the Hospital recorded that Extrapontine Myelinosys (EPM) in the patient as the cause of death, but could not explain the reason for the same.

“Having arrived at the conclusion that the mystery of recording EPM in the discharge summary issued by the Hospital could not be explained by the Hospital or by the learned counsel appearing for the opposite parties, the same reflects upon the manner in which the discharge summary was deficiently issued,” observed the Commission.

The history of the case goes back to 2012 when the complainant’s mother was suffering from gastrological problems and was taken to the treating hospital.  In the complaint, the patient’s son alleged negligence in the treatment rendered by the hospital and doctors in the administration of drugs- Lasix and Mannitor. He claimed that these drugs were administered unregulated and were incorrectly prescribed which resulted in electrolyte imbalance in the patient and consequently, the deceased patient suffered permanent brain damage arising out of a rare and deadly neuro problem, Extrapontine Myelinosys (EPM)/Centralpontine Myelinosys (CPM).

The complainant alleged that a wrong line of treatment was adopted. He further alleged that the treating doctors adopted an extremely erroneous rapid correction method for maintaining the level of sodium deficiency (hyponatremia).

It was alleged by the complainant, a wrong line of treatment was adopted which was a clear negligence. Further, he claimed that the administration of the wrong dosage of drugs resulted in a heavy drainage of fluids from the patient’s body causing a severe electrolyte imbalance. Thereafter, they allegedly attempted rapid correction measures which were carelessly deficient and were without the availability of a pathological report for at least 30 hours.

The counsel for the complainant contended that the detection of a low sodium level occurred after 30 hours of the admission of the patient by which time, her brain had permanently been damaged and shortly thereafter the situation became irreversible. This came to be reflected later on with the MRI that was conducted and the report whereof was analyzed and repeatedly indicated in the symptoms and diagnosis recorded by the doctors themselves. It was alleged that this permanent damage on account of wrong line of treatment and negligent approach was conclusively recorded by the hospital in the discharge summary as “CVA-Left Basal Ganglia Infarct with Metabolic Encephalopathy with Extrapontine Myelinolysis with HTN.” Extrapontine Myelinolysis (EPM), is caused on account of electrolyte imbalance.

While considering the complaint, both the Uttarakhand State Medical Council and the Delhi Medical Council had exonerated the doctors holding that there was no medical negligence. Even the erstwhile Medical Council of India had also observed that “the team of doctors involved in the treatment managed her clinical condition to the best of their medical knowledge and prudence and no negligence is apparent on the part of the treating doctors.”

The complainant’s counsel cited medical literature on Furosemide i.e. Lasix and Mannitol to urge that if a high dose of Lasix is administered, it reduces sodium content and increase excretion which results in electrolyte imbalance and dehydration. He further urged that the medical protocols were not followed and there was no constant monitoring.

While considering the complaint, the consumer court compared the literature which was cited by the Complainant and noted that “…it is evident that the administration of the drug is for the said purpose and it has to be administered with cautious monitoring. Thus, it is not a prohibited drug and rather is an advisable drug as per medical protocol to reduce Hyper Tension. The contention on behalf of the Complainant that Lasix was incorrectly advised therefore does not seem to be correct. There is no adverse comment regarding the drugs in the expert opinions referred.”

“Thus, so far as the Opposite Party No.3 (gastroenterologist) is concerned, it cannot be said that he had advised the administration of Lasix against medical protocol for reducing the Hyper Tension of the patient which was recorded at the time of her admission as 190/110,” it further noted.

Similarly, the Commission noted that the drug Mannitol was also correctly prescribed. In this regard, the Commission observed, “It appears from the literature as cited by the Complainant that Mannitol is a drug meant for reduction of intracranial pressure and cerebral edema as well as intraocular pressure. The literature advises that before administering Mannitol fluid and electrolyte imbalances should be corrected. Consequently serum electrolytes need to be monitored. The drug seems to have been prescribed looking to the mental state of the patient on 26.10.2012. There is no material to accept that the administration of the drug was wrongly prescribed.”

While considering the question of whether the electrolyte balances that emerged were managed appropriately or not or did they result in causing EPM or CPM as alleged by the Complainant, the consumer court noted that even the Neurologist, who was treating the patient, could not come to any conclusion based on the MRI report that the patient was suffering from EPM.

Further, the Commission noted that the medical protocol including the MRI Brain Scan Test was carried out that did not indicate any adverse any adverse symptom relating to EPM or CPM. “There is no material to contradict the aforesaid process adopted by the Doctors in order to construe that appropriate medical protocol was not followed and that they were deliberately negligent. It is equally true that the patient’s condition did not improve but there was nothing to indicate that the patient was at that moment suffering from any excessive infusion, as alleged to accept the suggestion of Iatrogenic Hypernatremia,” noted the Commission.

The Consumer Court observed that a third MRI was conducted on 31.10.2012 and the report reflected Metabolid Encephalopathy. Even this report did not record EPM, noted the Commission, adding that the “report of UP State Medical Council dated 02.12.2014 wrongly records of confirmation of EPM through the subsequent MRI report.”

“Learned Counsel for the Opposite Parties have submitted that this MRI report is final and the same has been taken into consideration by the experts of the Delhi Medical Council and their opinion has been affirmed by the Medical Council of India. Not only this, the report of the Maulana Azad Medical College dated 04.10.2019 has approved the same holding that the Doctors have exercised their skill to the best of their capacity, knowledge and prudence and therefore, no negligence is made out,” it further observed.

At this outset, the Commission was considering the question as to why the Hospital in the discharge summary dated 23.11.2012 recorded in its conclusion the initial diagnosis of EPM being also as one of the symptoms along with ME and hypertension.

“The said discharge summary is on record and the final diagnosis recorded therein has already been noted in paragraph (2) of this order. Assuming that the expert opinions of the Medical Councils of Delhi and India, and that of Maulana Azad Medical College are correct, as urged on behalf of the Opposite Parties, the discharge summary reflects partly to the contrary and indicates a final diagnosis of EPM as well recorded by the Hospital itself. The question is did the Doctors and the Hospital manage the patient with care and precaution and as to whether their own final diagnosis was medically correct. On a specific question being put to the learned Counsel for the Opposite Parties, particularly, Opposite Parties No.2 and 3 as well as Mr. Pattjoshi appearing for the Hospital, no explanation could be given by them about the said conclusion drawn and recorded in the discharge summary of the Hospital itself. The said conclusion records hypertension and ME with Extrapontine Myelinolysis (EPM),” the Commission observed.

Noting that EPM is caused on account of electrolyte imbalance, the Commission observed,

“The electrolyte imbalance is evident from the fact that the Opposite Parties (hospital, neurologist, gastroenterologist, ICU in charge, and 2 ICU doctors) themselves have come up with a case that all corrective measures were adopted to secure the balance of the sodium level. It is this which is being defended by the Opposite Parties contending that they could not have managed it in a better way in their assessment and judgment to correct the imbalance that was done, as per medical protocol.”

The Commission noted that to justify the time period for adopting the correct protocol the authorities relied on two MRI reports dated 26.10.2012 and 29.10.2012 to urge that since there was no confirmed symptom of either ME or EPM in those two MRI reports, the electrolyte balance and sodium was being monitored on the assumption that no such symptom had set in so as to adopt any other medical protocol.

“In such a situation, the suggestion of the Complainant to infuse hypertonic saline 3% could not have been adopted as that would have been fatal. It is correct that there is no such material adduced on behalf of the Complainant to demonstrate that the infusion of hypertonic saline 3% was essentially the only way out in these circumstances when the sodium level of the patient was admittedly fluctuating. The opinion of the experts of the Delhi Medical Council, the Medical Council of India and the Maulana Azad Medical College is clearly indicative that no negligence can be inferred on that count,” it further noted.

Therefore, the Commission noted that the conclusion, drawn by the Hospital in its discharge summary about EPM seemed to be not in tune with the subsequent expert opinions or the arguments made by the Complainant. Further, the Commission observed that the counsel for the hospital and doctors were not able to give any explanation as to why the discharge summary recorded the symptoms of EPM also existing along with hypertension and ME.

The Commission observed that the discharge summary was prepared with a “definite conclusion and is a report expressing the opinion about the symptoms of the patient the medical expert reports discussed hereinabove are correct, and there is no reason to doubt the same, then, can it be said that the conclusion drawn in the discharge summary is erroneous.”

At this outset, the Commission further noted,

The conclusion of EPM as one of the symptoms in the discharge summary confirms the suspicion raised earlier, nonetheless if the same is in contrast with the final medical reports and expert opinions sought by this Commission, then can it be termed as conclusive. Such a recital cannot be termed as an error of judgment as it is not a symptom suggested in the alternative, but is recorded along with PE and hyper tension but if this recording of an opinion in the discharge summary is erroneous then in that event this is also negligence inasmuch as without confirming the cause, the fact being reported by the Hospital finally is not an error of judgment but is negligence as no such opinion can be rendered casually.”

“On the other hand, if the opinion is correctly recorded, then the claim set up by the Complainant right from the beginning cannot be doubted. Either way if the recording of the EPM in the discharge summary is negligence or otherwise if it is correct, then even if the medical protocols were observed while treating the patient, this recording of the symptom in the discharge summary by the Hospital is clear negligence. May be it is for this reason that the Medical Council commented upon a faulty record keeping of Hospital papers by the Opposite Parties,” the Commission observed at this outset.

However, the Commission noted that the expert reports held that there was no medical negligence on the part of the treating doctors.

“There is no clear opinion by the experts as to why the discharge summary records the possibility of EPM yet on its own the experts have opined that the diagnosis and the treatment by the doctors was in accordance with protocol and did not suffer from any deficiency or negligence,” noted the Commission.

The NCDRC bench concluded that while the hospital and doctors could not explain the “mystery of recording EPM in the discharge summary”, the Commission noted that the same reflected the manner in which the discharge summary was deficiently issued. 

Therefore, holding the Hospital liable, the Commission observed,

“This seems to have been one of the major elements for raising a challenge by the Complainant and therefore the hospital is directly and vicariously liable for those who recorded the discharge summary indicating that one of the causes of the death of the patient was due to EPM. The Hospital therefore cannot be absolved of its liability in a complete absence of any explanation on that score. No right of silence is available as the Hospital was obliged to disclose as to how the discharge summary consciously included EPM as one of the causes of death. There could be a myriad number of explanations but the medical journey of the deceased and the symptoms cannot be conclusively said to be unconnected with EPM. This could have been explained by the Hospital either before the experts or before this Commission, but the learned counsel expressed their helplessness to explain the recording of such a fact.”

“In the above circumstances, the complaint deserves to be partly allowed for negligence and deficiency in service by the Opposite Party/Hospital that has issued the discharge summary recording EPM as also one of the symptoms causing brain damage. The issuance of a discharge summary in the circumstances above therefore renders it to be an opinion on EPM which remains unexplained. This lack of explanation about the correctness or otherwise of the recital of the symptom of the EPM in the discharge summary is an avoidance that creates a great disadvantage to the Complainant who had founded the Complaint believing the said recital to be correct. The document therefore according to the Opposite Parties results in a deception or otherwise attempts a deliberate conclusion which in the opinion of this Commission is a gross negligence and an unpardonable serious deficiency on the part of the Hospital,” it further noted.

Accordingly, the Commission directed the Hospital to pay a lumpsum amount of Rs 25 lakh and ordered, “Accordingly for this negligence and deficient conduct on the part of the hospital a lump sum amount of Rs.25 lakhs is imposed on the Opposite Party No.1 (hospital) for the aforesaid reasons coupled with 6% interest thereon from the date of the issuance of the discharge summary till the date of actual payment of the amount quantified above with in a period of 3 months from today.”

To view the order, click on the link below:

https://medicaldialogues.in/pdf_upload/kailash-hospital-245254.pdf

Also Read: Patient dies after wrong injection at Neyyattinkara General Hospital, State Human Rights Commission orders probe

Powered by WPeMatico

Ayodhya’s Rajarshi Dashrath Medical College set to open 110-bed trauma centre by May 2025

Ayodhya: As part of the state government’s scheme to develop Ayodhya into a hub of health and wellness, the Uttar Pradesh government has greenlit the construction of a state-of-the-art 110-bed trauma centre at the Rajarshi Dashrath Medical College, Darshan Nagar, Ayodhya.  

The project with an estimated budget of Rs 33 crore, is expected to be completed by May 2025. The facility will include a 50-bed trauma centre and a 60-bed emergency medicine department, providing comprehensive emergency medical services with a total capacity of 110 beds.  

It will offer comprehensive modern healthcare services to patients under one roof, which will save the residents of Ayodhya from travelling to Lucknow for the treatment of emergency cases. Ayodhya will become a hub of both spirituality and advanced healthcare.  

Also read- Ram Mandir Pran Pratishtha: Beds reserved at district hospitals, AIIMS experts training doctors

According to an official spokesperson, the trauma centre is part of the broader blueprint for Ayodhya’s development, which began with the construction of the Ram Temple. 

“Concerned about the health needs of both residents and devotees, CM Yogi has directed the expansion of facilities at the multi-speciality hospital and Rajarshi Dashrath Medical College in Darshan Nagar,” the spokesperson told TOI

Following government approval, the UP State Construction and Infrastructure Development Corporation Limited (UPSIDCO) initiated the project, and 50 per cent of the work on the three-storey building has already been completed.

Speaking to Daily Pioneer, Principal Dr Gyanendra Kumar said, “The construction is progressing rapidly, and the centre will also feature a modern lift for added convenience. This trauma centre will be a major asset for critically ill patients, offering all necessary services in one place, eliminating the need for patients and their families to travel between facilities.”  

Also Read: CMC Vellore gets Rs 500 crore grant from Azim Premji Foundation to set up a new medical college at Chittoor

Powered by WPeMatico

DCI directs Dental Colleges to implement measures to curb ragging menace

Delhi: The Dental Council of India (DCI) has issued guidelines for curbing the menace of ragging in dental institutions.

Writing to the Principals/Heads of all the Dental Colleges in the Country, the DCI stated that it is the responsibility of all institutions to ensure that no incident of ragging takes place n their dental institution and measures taken to curb it may be reviewed as DCI Regulations on Curbing the Menace of Ragging in Dental Colleges, 2009.

As per section 11.3 of the regulations above, the authorities/Management (Trust, Societies, etc.) of the institution, particularly the Head of the institution, shall be responsible for ensuring that no incident of ragging takes place in the institution. In case any ragging incident occurs, the Management/Head shall take prompt and appropriate action against the person(s) whose dereliction of duty lead to the incident. In its turn, the authority designated to appoint the Head shall take prompt and appropriate action against the Head.

Further, DCI has instructed all dental institutions should issue advertisements against ragging through signboards, pamphlets etc. before the commencement of academic year as well as during the midst of the session and also to issue booklets to all the students of your Institutions containing the details about what constitutes ragging, punishable ingredients of ragging, punishments and penalty for ragging, names and mobile numbers of the members of the Anti Ragging Squad, Anti Ragging Committee (Anti Ragging Helpline), Wardens, Deputy Wardens of Men’s and Women’s hostel.

All dental Institutions will have to designate any of their faculty member(s) as “Counsellor” for fresher and senior students to coordinate the batches of students (Counselees) regularly about day-to-day problems and also to sensitize their role in curbing the menace of ragging.

The dental colleges will have to obtain and file an undertaking, on anti-ragging, from all parents/guardians and students (1st year to final year) studying in BDS/MDS/PG Diploma/Para Dental Courses or any other course approved/recognized by DCI

Besides above, it is also pertinent to mention here that, as per section 12.1 of subject regulations, each and every institution shall submit its reports by 31st October of every year in which admissions are made, indicating the action taken by institution for implementation of Regulation 9.1 & 9.2 of said regulations failing which the Dental Council of India, 

In case the institutes fail to submit the report, then DCI, as per section 11.4 of Regulations on Curbing the Menace of Ragging in Dental Colleges, 2009, shall impose any one or any combination of the following penalties on it –

To initiate the derecognition process against the institution under section 16A of the Dentists Act, 1948

To reduce the admission capacity of the institution to the extent to which the Council deem fit.

To stop further admission in the institution till further orders.

To stop renewal of permission in respect of UG/PG Dental Courses.

To post the information regarding penalties so imposed on the concerned institution on the website of DCI for information of all concerned.

DCI has developed an online module to upload the requisite information/documents on its website to reduce the paperwork and efficiently scrutinize the above data. The Executive Committee of the DCI, in its meeting held on 13th October 2018 in New Delhi, has decided that all the requisite information/documents required as per DCI Regulations on Curbing the Menace of Ragging in Dental Colleges, 2009 shall be uploaded on the DCI website and any hard copy of information /documents received by Post or sent by E-mail shall not be considered by DCI.

DCI stated that it is mandatory for all the institutions to upload the Anti Ragging Report, October 2024 on DCI Anti Ragging Online Module by using the online portal, as per the Monitoring Committee appointed by the Hon’ble Supreme Court of India and as per DCI Regulations on Curbing the Menace of Ragging in Dental Colleges, 2009, latest by 31.10.2024, positively. In case the requisite information is not uploaded by 31.10.2024 on DCI Anti Ragging Online Module, the name of defaulting college/institution will be forwarded to the said Monitoring Committee for appropriate action and their names will also be uploaded on DCI Website.

It is again reiterated that only the uploaded Anti Ragging Report, Oct. 2024 will be considered by the council and no hard copy/emails will be considered as report submission. Compliance to this circular may be treated as most urgent since the DCI Anti Ragging Online Module will automatically get disabled for uploading October 2024 Anti Ragging Report after 31.10.2024 (Midnight), the dental council said.

To view the official Notice, Click here :  https://medicaldialogues.in/pdf_upload/5791-256276.pdf

Powered by WPeMatico

Biotechnology to Drive India’s Next Industrial Revolution: Dr. Jitendra Singh

New Delhi: Union Minister of State for Science and Technology, Jitendra Singh, highlighted India’s expanding role as a global leader in affordable, high-quality healthcare and medical tourism, which has emerged as a major source of revenue.

Singh was addressing the CII 6th Pharma and Life Sciences Summit 2024 in New Delhi on Wednesday as he expressed government’s commitment to supporting the biotechnology sector, referencing the launch of venture funds and policies that have spurred significant growth in biotech startups.

“The number of biotech start-ups has risen from just 50 in 2014 to over 5,000 now, reflecting India’s increasing focus on bio economy and urged for stronger collaboration between the public and private sectors,” Singh said.
Singh also highlighted the need to create a robust research ecosystem, with biotechnology being a focal point for the next industrial revolution.
Singh further emphasized on the growth of India’s bioeconomy, which has seen a ten-fold increase since 2014, and reiterated the need for an inclusive innovation ecosystem that balances intellectual property, data protection, and clinical trials.
His remarks reflected optimism for India’s role as a global leader in healthcare and biotechnology, while also addressing the challenges and opportunities ahead.
Dr Arunish Chawla, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, underscored the significant milestones of, the pharmaceuticals and biotechnology sector “Last month, the pharmaceuticals and biotechnology became the 4th largest export manufacturing Industry for India. India is aiming to be a reliable pharmacy of the world and a futuristic global leader in both biotechnology and life sciences”.
Dr Rajesh S Gokhale, Secretary, Department of Biotechnology, Ministry of Science and Technology, Government of India in his address emphasized on the futuristic role that biotechnology can play in the progress of India, highlighting global recognition and collaboration.
He underscored the BioE3 Policy – the importance of biotechnology in driving economic growth, protecting the environment, and generating employment. He noted that India’s path towards ‘Viksit Bharat 20247’ requires breaking out of the ‘middle-income trap’, a challenge faced by several countries.
Dr Rajeev Singh Raghuvanshi, Drugs Controller General India, Central Drugs Standard Control Organization (CDSCO) highlighted India’s strides toward becoming the ‘pharmacy of the world’, commending regulatory improvements under CDSCO.
He emphasized India’s commitment to global public health through collaborative efforts, including new approaches to streamline drug approvals, reduce delays, and increase efficiency.
Dr Vinod K Paul, Member, NITI Aayog highlighted the significant milestones achieved in pandemic preparedness, emphasizing the importance of collaboration across government, industry, and research ecosystems. He outlined four key focus areas: government policy, data management, innovation & manufacturing, and global partnerships. He stressed the need for proactive R&D, particularly in developing countermeasures for future pandemics, and the necessity of preparedness through rapid vaccine development.
Dr Rajesh Jain, Chairman, CII National Committee on Biotechnology and Chairman & Managing Director, Panacea Biotec Ltd) in his address highlighted the need for the pharmaceutical and biotechnology sectors to triple in size, aiming to reach USD 300 billion by 2047.
The CII Life Sciences Summit is an annual flagship thought leadership platform. It is a synergistic combination of the pharmaceutical and biotechnology sectors and a platform dedicated to discuss the impact of the regulatory reforms, recent technological trends, fostering cutting-edge innovations, the future of biologics and biosimilar, developing skilled talent, ensuring equitable healthcare, and other prevalent advocacy matters.

Powered by WPeMatico